CEO: Jacob Odeberg
CytaCoat operates a virtual biotech model in which a core group of highly experienced scientific and commercial decision makers lead the organisation and are supported by external CRO’s, suppliers and expert networks.
Our proprietary platform technology provides a unique, universal and covalent antibacterial coating.
The CytaCoat technology is based on a discovery, where our proprietary polymer surface exhibits a clear effect on several of the most dangerous pathogenic bacteria that pose problems in healthcare today. CytaCoat’s surface exhibits a antibacterial effect on both gram-negative and gram- positive bacteria, the two main groups of bacterial strains.